Levobupivacaína Altan (Levobupivacaine)

Levobupivacaine works by binding reversibly to voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents sodium influx, blocking the initiation and propagation of action potentials, which results in a temporary loss of sensory and motor function in the region supplied by the blocked nerves.

The specific dose and concentration of Levobupivacaína Altan are determined by the prescribing clinician based on the type of procedure, patient characteristics, and desired depth of block. Healthcare providers calculate the appropriate amount according to established clinical guidelines and individual patient needs.

Safety data for levobupivacaine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the supervision of a qualified obstetric or anesthetic specialist.

To order Levobupivacaína Altan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levobupivacaína Altan contains levobupivacaine, the S‑enantiomer of bupivacaine. Compared with racemic bupivacaine, it offers a similar duration of anesthesia but with a lower incidence of cardiotoxicity and central nervous system toxicity, making it a preferred option when safety margins are a priority.

Store Levobupivacaína Altan at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperatures. Inspect the vial for particulate matter or discoloration before use and discard if any abnormalities are observed.

Levobupivacaína Altan is administered by an experienced anesthesiologist or qualified practitioner via epidural injection. The drug is injected into the epidural space using aseptic technique, and the dosage is titrated to achieve the desired level of sensory and motor block while monitoring the patient continuously.

Serious risks include cardiac arrhythmias, severe hypotension, central nervous system toxicity such as seizures, respiratory depression, and rare complications like spinal or epidural hematoma. Prompt recognition and supportive management are essential; therefore, continuous cardiovascular and neurological monitoring is required during and after administration.

Levobupivacaína Altan should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with significant cardiac conduction abnormalities, severe heart block, or uncontrolled arrhythmias. Caution is also advised in patients receiving anticoagulant therapy or who have coagulopathies due to the risk of spinal hematoma.